DexCom
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 3 days.
- Recent price momentum is +11.8% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has fallen to 4.3% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-21 20:27 UTC
Data coverage: 6 of 6 factors. Missing data is not a zero score.
Valuation C
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 31.2x | Better than 21% |
| Forward P/E | 27.3x | Better than 21% |
| Price / Sales | 5.8x | Better than 19% |
| P/E vs own 5-yr range | 6th pctl | Better than 94% |
Growth A
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 17.0% | Better than 78% |
| Net income CAGR (3Y) | 34.8% | Better than 83% |
| Free cash flow CAGR (3Y) | 52.3% | Better than 85% |
Profitability A
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 60.1% | Better than 74% |
| Operating margin | 19.6% | Better than 75% |
| Net margin | 17.9% | Better than 76% |
| Return on equity | 34.5% | Better than 90% |
| Return on invested capital | 17.3% | Better than 86% |
Momentum B+
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -14.1% | Better than 41% |
| 6-month return | 10.0% | Better than 72% |
| 12-month return (ex latest month) | 30.0% | Better than 69% |
| Distance below 52-week high | 14.3% | Better than 73% |
Financial Health B+
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 1.9x | Better than 53% |
| Debt to assets | 21.9% | Better than 53% |
| Interest coverage | 60.5x | Better than 91% |
| Free cash flow / net income | 128.8% | Better than 57% |
Analyst View B
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 93.3% | Better than 76% |
| Upside to average target | 25.1% | Better than 41% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 80.19
- Open
- 80.48
- Day range
- 78.75 - 81.58
- Avg price
- 79.69
- Volume
- 4.61M
- Turnover
- 367.25M
- Turnover ratei
- 1.24%
- Volume ratioi
- 1.07
- Amplitudei
- 3.53%
- 52-week rangei
- 56.72 - 92.59
Valuation
- P/Ei
- 37.95
- P/E (TTM)i
- 31.23
- P/Bi
- 11.67
- EPSi
- 2.09
- Book value / shi
- 6.80
- Net profit
- 779.47M
- Net assets
- 2.54B
Share structure
- Market cap
- 29.58B
- Float capi
- 29.48B
- Shares out
- 372.95M
- Float sharesi
- 371.61M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2005-04-14
14.3% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-57.18M net over the window
Short interest
- Shares short
- 15.93M
- % of floati
- 4.27%
- Days to coveri
- 2.81
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of DexCom (DXCM)?
DexCom last traded at 79.32. This page shows a periodic quote snapshot. Check the displayed quote time.
What is DexCom's market cap?
About 29.58B.
What is the P/E ratio of DexCom?
The trailing twelve-month P/E is 31.23, below its own 5-year average of 106.28 — toward the bottom of its historical range (5.66% percentile). See the Valuation tab for the full history.
Does DexCom pay a dividend?
DexCom does not currently pay a regular dividend.
Is DexCom a buy according to analysts?
The consensus of 15 analysts is a Buy rating, with an average 12-month price target of 99.21, which implies 25.1% upside from the current price. This is not investment advice.
What is DexCom's StockVane Quant Rating?
The StockVane Momentum strategy currently rates DexCom a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 20:02:21 · For reference only, not investment advice and not tailored to your situation.
DexCom discussion 0 comments